Funds › Opaleye Management Inc.
Opaleye Management Inc.
13F for Q2 2026, filed Aug 14, 2026. 58 positions worth $1.1B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$1.1B
+$345.0M (45.4%) vs Q1 2026
Positions
58
54 in Q1 2026
Top 10 share
64.8%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Opaleye Management Inc. in the latest 13F quarter?
Using 13F.ai, how has Opaleye Management Inc.'s portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Opaleye Management Inc.'s top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | LQDA Liquidia Corporation | 2.45M | $195.1M | 17.7% | -3.8% | 13F ↗ |
| 2 | ETON Eton Pharmaceuticals, Inc. | 2.86M | $103.5M | 9.4% | Unchanged | 13F ↗ |
| 3 | HROW Harrow, Inc. | 2.40M | $101.9M | 9.2% | -15.3% | 13F ↗ |
| 4 | IRON Disc Medicine, Inc. | 855,000 | $62.5M | 5.7% | +103% | 13F ↗ |
| 5 | URGN UroGen Pharma Ltd. | 1.44M | $53.0M | 4.8% | +0.7% | 13F ↗ |
| 6 | Apogee Therapeutics Inc | 390,000 | $51.8M | 4.7% | Unchanged | 13F ↗ |
| 7 | MGTX MeiraGTx Holdings plc | 3.55M | $48.0M | 4.3% | +67.2% | 13F ↗ |
| 8 | SLGL Sol-Gel Technologies Ltd. | 500,000 | $37.1M | 3.4% | Unchanged | 13F ↗ |
| 9 | RZLT Rezolute, Inc. | 6.30M | $32.8M | 3.0% | Unchanged | 13F ↗ |
| 10 | TGTX TG Therapeutics, Inc. | 535,000 | $29.4M | 2.7% | Unchanged | 13F ↗ |
| 11 | IMMX Immix Biopharma, Inc. | 2.35M | $24.2M | 2.2% | New | 13F ↗ |
| 12 | CBIO Crescent Biopharma, Inc. | 1.32M | $23.7M | 2.2% | +0.5% | 13F ↗ |
| 13 | STOK Stoke Therapeutics, Inc. | 700,000 | $22.9M | 2.1% | Unchanged | 13F ↗ |
| 14 | ACOG Alpha Cognition Inc. | 2.90M | $20.9M | 1.9% | +13.0% | 13F ↗ |
| 15 | EWTX Edgewise Therapeutics, Inc. | 500,000 | $20.3M | 1.8% | Unchanged | 13F ↗ |
| 16 | RVMD Revolution Medicines, Inc. | 100,000 | $18.7M | 1.7% | Unchanged | 13F ↗ |
| 17 | GLUE Monte Rosa Therapeutics, Inc. | 745,000 | $18.0M | 1.6% | New | 13F ↗ |
| 18 | ALMS Alumis Inc. | 550,000 | $15.5M | 1.4% | Unchanged | 13F ↗ |
| 19 | CDXS Codexis, Inc. | 6.79M | $15.3M | 1.4% | Unchanged | 13F ↗ |
| 20 | REPL Replimune Group, Inc. | 1.38M | $15.3M | 1.4% | New | 13F ↗ |
| 21 | Xoma Royalty Corporation | 338,374 | $14.4M | 1.3% | +12.8% | 13F ↗ |
| 22 | MBX MBX Biosciences, Inc. | 260,000 | $14.4M | 1.3% | Unchanged | 13F ↗ |
| 23 | RYTM Rhythm Pharmaceuticals, Inc. | 122,500 | $13.6M | 1.2% | -0.4% | 13F ↗ |
| 24 | EDIT Editas Medicine, Inc. | 3.86M | $12.5M | 1.1% | +100% | 13F ↗ |
| 25 | PTGX Protagonist Therapeutics, Inc. | 100,000 | $12.3M | 1.1% | Unchanged | 13F ↗ |
| 26 | CABA Cabaletta Bio, Inc. | 3.86M | $12.0M | 1.1% | +180% | 13F ↗ |
| 27 | QTTB Q32 Bio Inc. | 931,000 | $11.9M | 1.1% | -25.9% | 13F ↗ |
| 28 | ANNX Annexon, Inc. | 1.71M | $9.8M | 0.9% | -26.5% | 13F ↗ |
| 29 | VSTM Verastem, Inc. | 1.80M | $6.9M | 0.6% | New | 13F ↗ |
| 30 | ZNTL Zentalis Pharmaceuticals, Inc. | 1.41M | $6.9M | 0.6% | Unchanged | 13F ↗ |
| 31 | RLMD Relmada Therapeutics, Inc. | 935,000 | $6.5M | 0.6% | Unchanged | 13F ↗ |
| 32 | OCUL Ocular Therapeutix, Inc. | 600,000 | $5.9M | 0.5% | Unchanged | 13F ↗ |
| 33 | TRVI Trevi Therapeutics, Inc. | 310,000 | $5.8M | 0.5% | -10.2% | 13F ↗ |
| 34 | BBOT BridgeBio Oncology Therapeutics, Inc. | 700,000 | $5.3M | 0.5% | +1214% | 13F ↗ |
| 35 | LYEL Lyell Immunopharma, Inc. | 344,025 | $4.8M | 0.4% | +335% | 13F ↗ |
| 36 | IRD Opus Genetics, Inc. | 1.13M | $4.6M | 0.4% | +0.4% | 13F ↗ |
| 37 | FDMT 4D Molecular Therapeutics, Inc. | 334,437 | $4.4M | 0.4% | +198% | 13F ↗ |
| 38 | NTLA Intellia Therapeutics, Inc. | 250,000 | $4.2M | 0.4% | +2.0% | 13F ↗ |
| 39 | VYGR Voyager Therapeutics, Inc. | 1.19M | $4.1M | 0.4% | +3.0% | 13F ↗ |
| 40 | BDSX Biodesix, Inc. | 180,000 | $4.1M | 0.4% | -24.4% | 13F ↗ |
| 41 | RCKT Rocket Pharmaceuticals, Inc. | 1.00M | $3.4M | 0.3% | +4.7% | 13F ↗ |
| 42 | JBIO Jade Biosciences, Inc. | 145,000 | $3.2M | 0.3% | -66.1% | 13F ↗ |
| 43 | SNWV SANUWAVE Health, Inc. | 306,140 | $3.1M | 0.3% | -68.8% | 13F ↗ |
| 44 | FBIO Fortress Biotech, Inc. | 890,000 | $2.7M | 0.2% | -14.6% | 13F ↗ |
| 45 | DERM Journey Medical Corporation | 350,000 | $2.5M | 0.2% | -63.5% | 13F ↗ |
| 46 | PHAT Phathom Pharmaceuticals, Inc. | 185,589 | $2.0M | 0.2% | New | 13F ↗ |
| 47 | INBX Inhibrx Biosciences, Inc. | 20,291 | $1.9M | 0.2% | New | 13F ↗ |
| 48 | ENTA Enanta Pharmaceuticals, Inc. | 125,000 | $1.8M | 0.2% | Unchanged | 13F ↗ |
| 49 | COAG Hemab Therapeutics Holdings, Inc. | 47,652 | $1.8M | 0.2% | New | 13F ↗ |
| 50 | TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 65,000 | $1.3M | 0.1% | New | 13F ↗ |
Showing the top 50 of 58 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
13 new, 15 added to, 13 trimmed, 9 exited, 17 unchanged. By estimated dollars.
New positions (13)
| IMMX Immix Biopharma, Inc. | 2.35M | New | $24.2M |
| GLUE Monte Rosa Therapeutics, Inc. | 745,000 | New | $18.0M |
| REPL Replimune Group, Inc. | 1.38M | New | $15.3M |
| VSTM Verastem, Inc. | 1.80M | New | $6.9M |
| PHAT Phathom Pharmaceuticals, Inc. | 185,589 | New | $2.0M |
| INBX Inhibrx Biosciences, Inc. | 20,291 | New | $1.9M |
| COAG Hemab Therapeutics Holdings, Inc. | 47,652 | New | $1.8M |
| TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 65,000 | New | $1.3M |
| BHVN Biohaven Ltd. | 77,915 | New | $1.2M |
| KTTA Pasithea Therapeutics Corp. | 2.05M | New | $1.1M |
Added to (15)
| IRON Disc Medicine, Inc. | 855,000 | +103% | $31.7M |
| MGTX MeiraGTx Holdings plc | 3.55M | +67.2% | $19.3M |
| CABA Cabaletta Bio, Inc. | 3.86M | +180% | $7.7M |
| EDIT Editas Medicine, Inc. | 3.86M | +100% | $6.3M |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 700,000 | +1214% | $4.9M |
| LYEL Lyell Immunopharma, Inc. | 344,025 | +335% | $3.7M |
| FDMT 4D Molecular Therapeutics, Inc. | 334,437 | +198% | $3.0M |
| ACOG Alpha Cognition Inc. | 2.90M | +13.0% | $2.4M |
| Xoma Royalty Corporation | 338,374 | +12.8% | $1.6M |
| URGN UroGen Pharma Ltd. | 1.44M | +0.7% | $367.9K |
Trimmed (13)
| HROW Harrow, Inc. | 2.40M | -15.3% | -$18.4M |
| LQDA Liquidia Corporation | 2.45M | -3.8% | -$7.8M |
| SNWV SANUWAVE Health, Inc. | 306,140 | -68.8% | -$6.8M |
| JBIO Jade Biosciences, Inc. | 145,000 | -66.1% | -$6.3M |
| CGON CG Oncology, Inc. | 17,789 | -81.2% | -$5.5M |
| DERM Journey Medical Corporation | 350,000 | -63.5% | -$4.3M |
| QTTB Q32 Bio Inc. | 931,000 | -25.9% | -$4.1M |
| ANNX Annexon, Inc. | 1.71M | -26.5% | -$3.5M |
| BDSX Biodesix, Inc. | 180,000 | -24.4% | -$1.3M |
| TRVI Trevi Therapeutics, Inc. | 310,000 | -10.2% | -$654.6K |
Exited (9)
| CATX Perspective Therapeutics, Inc. | 4.67M | Exited | -$19.5M |
| Assertio Holdings Inc Cs | 265,707 | Exited | -$5.1M |
| STRO Sutro Biopharma, Inc. | 190,671 | Exited | -$4.7M |
| TECX Tectonic Therapeutic, Inc. | 123,000 | Exited | -$3.8M |
| RIGL Rigel Pharmaceuticals, Inc. | 70,000 | Exited | -$1.9M |
| NXTC NextCure, Inc. | 141,181 | Exited | -$1.5M |
| Perspective Therapeutics Inc | 200,000 | Exited | -$834.0K |
| PLX Protalix BioTherapeutics, Inc. | 340,000 | Exited | -$737.8K |
| LBRX LB Pharmaceuticals Inc | 14,506 | Exited | -$357.7K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 13F-HR | 58 | $1.1B | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 54 | $759.2M | Current | SEC ↗ |
| Q4 2025 | Apr 13, 2026 | 13F-HR/A (restatement) | 54 | $757.9M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 54 | $758.0M | Replaced | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 43 | $707.3M | Current | SEC ↗ |
| Q2 2025 | Aug 15, 2025 | 13F-HR/A (restatement) | 41 | $494.1M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 41 | $498.9M | Replaced | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 45 | $449.2M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer